2022 World Conference on Lung Cancer (ePosters)-EP08.01-021. Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy

EP08.01-021. Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy

Back to course

Pdf Summary

A phase 2 study is being conducted to evaluate the efficacy and safety of inupadenant in combination with chemotherapy in adults with nonsquamous non-small cell lung cancer (NSCLC) who have progressed on immunotherapy. Solid tumors, such as adenocarcinomas of the lung and colon, are often hypoxic and accumulate adenosine, which mediates immune suppression in the tumor microenvironment. Inupadenant is an antagonist of the high affinity A2A receptor (A2AR), which is responsible for immune suppression. It has shown preliminary evidence of clinical activity in multiple tumor types and has a favorable safety profile. The ongoing study aims to determine the recommended Phase 2 dose (RP2D) of inupadenant in combination with carboplatin and pemetrexed and compare the progression-free survival (PFS) between the active arm (inupadenant and chemotherapy) and the control arm (placebo and chemotherapy). Secondary objectives include evaluating changes in tumor size, overall response rate (ORR), and adverse events. Exploratory objectives involve the evaluation of biomarkers in the tumor and peripheral blood. The study population consists of adult patients with nonsquamous NSCLC who have relapsed or progressed after prior anti-programmed death (PD)-ligand (L)1 therapy. The sample size for the randomized part of the study is expected to be 150 participants. The study is being conducted to address the high unmet need for patients with NSCLC who have progressed on immunotherapy and may provide valuable information for further investigation of this combination therapy.

Asset Subtitle

Shouryadeep Srivastava,

Meta Tag

Speaker Shouryadeep Srivastava,

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

phase 2 study

inupadenant

chemotherapy

nonsquamous NSCLC

immunotherapy progression

A2A receptor

progression-free survival

overall response rate

biomarkers

combination therapy